Treatment of patients with HER2-mutant non-small-cell lung cancer with the pan-HER inhibitor pyrotinib in a phase 2 trial or compassionate use showed a favorable objective response rate, whereas patients treated in parallel by physician’s choice in a real-world study did not.
- Si-Yang Maggie Liu
- Hai-Yan Tu
- Yi-Long Wu